Dubensky Thomas W. 4
4 · ADURO BIOTECH, INC. · Filed Aug 11, 2017
Insider Transaction Report
Form 4
Dubensky Thomas W.
Chief Scientific Officer
Transactions
- Sale
Common Stock
2017-08-10$11.43/sh−40,912$467,665→ 39,900 total - Sale
Common Stock
2017-08-11$11.17/sh−9,088$101,538→ 39,900 total - Exercise/Conversion
Stock Option (Right to Buy)
2017-08-11−9,088→ 126,328 totalExercise: $1.00Exp: 2024-07-30→ Common Stock (9,088 underlying) - Exercise/Conversion
Common Stock
2017-08-11$1.00/sh+9,088$9,088→ 48,988 total - Exercise/Conversion
Stock Option (Right to Buy)
2017-08-10−40,912→ 135,416 totalExercise: $1.00Exp: 2024-07-30→ Common Stock (40,912 underlying) - Exercise/Conversion
Common Stock
2017-08-10$1.00/sh+40,912$40,912→ 80,812 total
Footnotes (4)
- [F1]The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2017.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.10 to $12.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.10 to $11.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]The shares subject to the Option vest in 48 equal monthly installments from the vesting commencement date of July 31, 2014.